Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

21.1%

53 terminated/withdrawn out of 251 trials

Success Rate

71.0%

-15.5% vs industry average

Late-Stage Pipeline

4%

11 trials in Phase 3/4

Results Transparency

44%

57 of 130 completed trials have results

Key Signals

33 recruiting57 with results36 terminated17 withdrawn

Enrollment Performance

Analytics

N/A
79(35.1%)
Phase 2
77(34.2%)
Phase 1
50(22.2%)
Phase 3
8(3.6%)
Early Phase 1
8(3.6%)
Phase 4
3(1.3%)
225Total
N/A(79)
Phase 2(77)
Phase 1(50)
Phase 3(8)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (251)

Showing 20 of 251 trials
NCT06904339Not ApplicableRecruiting

Communication About Sexual Health in Gynecologic Cancer

Role: lead

NCT07455032Phase 1Recruiting

Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas

Role: lead

NCT07517666Not ApplicableEnrolling By Invitation

Genetic Information for Families After Tumor Testing Study

Role: collaborator

NCT06089954Not ApplicableEnrolling By Invitation

Penn Medicine Biobank Return of Results Program

Role: collaborator

NCT04557423Not ApplicableCompleted

Evidence-Based Approach to Empower Asian American Women in Cervical Cancer Screening

Role: lead

NCT05923190Phase 2Active Not Recruiting

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

Role: lead

NCT04055311Not ApplicableCompleted

Recovery Support for Bladder Cancer Patients and Caregivers

Role: collaborator

NCT07471958Recruiting

Implementation of eHealth Delivery Alternatives for Cancer Genetic Testing for Hereditary Cancer (eREACH3)

Role: collaborator

NCT07188064Not ApplicableRecruiting

A Study Looking at a New Nerve Surgery to Help Men Regain Erections After Prostate Cancer Surgery

Role: collaborator

NCT07454499Not ApplicableNot Yet Recruiting

Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE)

Role: collaborator

NCT03992183Terminated

Utility of CAML as Diagnostic for Early Stage Lung Cancer

Role: lead

NCT07221942Phase 2Recruiting

Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma

Role: lead

NCT04455698Not ApplicableCompleted

Engaging and Activating Cancer Survivors in Genetic Services Study

Role: collaborator

NCT01208662Phase 3Active Not Recruiting

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Role: collaborator

NCT05427240Not ApplicableRecruiting

eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer

Role: collaborator

NCT03527108Phase 2Active Not Recruiting

Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC

Role: lead

NCT06782581Not ApplicableRecruiting

CARE Study: Cancer, Asian Americans, and Relationship Enrichment

Role: lead

NCT07221058Phase 1Recruiting

Adaptive Radiation Boost for Rectal Cancer

Role: lead

NCT05263050Phase 2Recruiting

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Role: lead

NCT05360732Phase 2Active Not Recruiting

Redefining FOLFIORINOX in Older Pancreatic Cancer Patients

Role: lead